A5068735332- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 and COVID-19 Research
- Genetics and Neurodevelopmental Disorders
- Neurogenesis and neuroplasticity mechanisms
- Bacteriophages and microbial interactions
- SARS-CoV-2 detection and testing
- Biosensors and Analytical Detection
- Protein Degradation and Inhibitors
- Bioeconomy and Sustainability Development
- Advanced biosensing and bioanalysis techniques
- Radiopharmaceutical Chemistry and Applications
- Neuroscience and Neuropharmacology Research
- Graphene and Nanomaterials Applications
- Lung Cancer Treatments and Mutations
- RNA Interference and Gene Delivery
- vaccines and immunoinformatics approaches
- Autism Spectrum Disorder Research
Biolog (United States)
2024
University of California, San Francisco
2020-2022
Pediatrics and Genetics
2017
California University of Pennsylvania
2017
William Penn University
2017
Abstract Targeted degradation of cell surface and extracellular proteins via lysosomal delivery is an important means to modulate biology. However, these approaches have limitations due lack modularity, ease development, restricted tissue targeting applicability both proteins. We describe a strategy, termed cytokine receptor-targeting chimeras (KineTACs), that addresses limitations. KineTACs are fully genetically encoded bispecific antibodies consisting arm, which binds its cognate receptor,...
Cyclin-dependent kinase-like 5 (CDKL5) deficiency is a neurodevelopmental disorder characterized by epileptic seizures, severe intellectual disability, and autistic features. Mice lacking CDKL5 display multiple behavioral abnormalities reminiscent of the disorder, but cellular origins these phenotypes remain unclear. Here, we find that ablating expression specifically from forebrain glutamatergic neurons impairs hippocampal-dependent memory in male conditional knock-out mice. Hippocampal...
Fragile X syndrome is a genetic condition resulting from FMR1 gene mutation that leads to intellectual disability, autism-like symptoms, and sensory hypersensitivity. Arbaclofen, GABA-B agonist, has shown efficacy in some individuals with FXS but become unavailable after unsuccessful clinical trials, prompting interest publicly available, racemic baclofen. The present study investigated whether baclofen can remediate abnormalities of neural circuit function, processing, behavior Fmr1...
Numerous neutralizing antibodies that target SARS-CoV-2 have been reported, and most directly block binding of the viral Spike receptor-binding domain (RBD) to angiotensin-converting enzyme II (ACE2). Here, we deliberately exploit non-neutralizing RBD antibodies, showing they can dramatically assist in neutralization when linked binders. We identified antigen-binding fragments (Fabs) by phage display bind RBD, but do not ACE2 or neutralize virus as IgGs. When these Fabs were assembled into...
Abstract Extracellular targeted protein degradation (eTPD) has emerged as a promising new drug modality focused on the elimination of pathogenic extracellular and transmembrane proteins. In contrast to intracellular degraders, which require ubiquitin-proteosome system, degraders can also harness endosomal-lysosomal pathways. EpiTACs are novel class bispecific antibody-based eTPD therapeutic, in one arm binds target interest, other degrading receptor. leverage atlas disease- tissue-enriched...
SUMMARY Current serology tests for SARS-CoV-2 antibodies mainly take the form of enzyme-linked immunosorbent assays or lateral flow assays, with former being laborious and latter expensive often lacking sufficient sensitivity scalability. Here we present development validation a rapid, low-cost solution-based assay to detect in serum, plasma, whole blood, saliva, using rationally designed split luciferase antibody biosensors (spLUC). This new assay, which generates quantitative results as...
Abstract Neutralizing agents against SARS-CoV-2 are urgently needed for treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify assemble synthetic human variable heavy (VH) domain binders with high affinity toward neutralizing epitopes without the need high-resolution structural information. We constructed VH-phage library targeted known site, angiotensin-converting enzyme 2 (ACE2) binding interface trimeric Spike receptor-binding (Spike-RBD). Using masked...
Abstract Extracellular targeted protein degradation (eTPD) has emerged as a promising new drug modality focused on elimination of extracellular and transmembrane proteins. In contrast to intracellular degraders, such proteolysis targeting chimeras (PROTACs) molecular glues which require ubiquitin-proteosome cellular pathways, degraders can additionally harness endosomal-lysosomal degradation. Two recently published examples include AbTACs (antibody-based PROTAC) co-engage interest (POI) E3...
Background: Fragile X syndrome (FXS) is a genetic condition which results from FMR1 gene mutation and leads to intellectual disability, autism-like symptoms sensory hypersensitivity. Arbaclofen, GABA-B agonist, showed efficacy for some individuals with FXS but was withdrawn clinical trials, prompting interest in publicly available, racemic baclofen. Methods: We investigated whether baclofen can remediate abnormalities of neural circuit function, processing and/or behavior Fmr1 knockout (KO)...